Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 33,591 matching trials from the live ClinicalTrials.gov search.
Conditions
Asthma
Interventions
FF 400 mcg, UMEC 500 mcg, FF/UMEC 400/500 mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Fibrillation, Atrial, Atrial Fibrillation
Interventions
SB424323
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Mobile, Alabama • Troy, Michigan • Akron, Ohio + 6 more
Conditions
Chronic Hepatitis C, Oxidative Stress
Interventions
silymarin, green tea extract (EGCG)
Drug · Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Ulcerative Colitis
Interventions
NX-13 250mg, NX-13 750mg, NX-13 Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Miami, Florida • Orlando, Florida • Tampa, Florida + 8 more
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.25% AR-12286 / 0.004% travoprost, 0.5% AR-12286, 0.004% travoprost, 0.004% Travoprost
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Inglewood, California • Newport Beach, California • Petaluma, California + 6 more
Conditions
Partial Epilepsy, Catamenial Epilepsy
Interventions
Ganaxolone, Placebo
Drug · Other
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
Conditions
Knee Osteoarthritis
Interventions
canakinumab, LNA043, Placebo to canakinumab
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
La Mesa, California • Clearwater, Florida • Sunrise, Florida + 2 more
Conditions
COVID-19
Interventions
MPV/S-2P
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Decatur, Georgia • Mineola, New York • Houston, Texas
Conditions
Hereditary Angioedema
Interventions
CINRYZE
Biological
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
7
States / cities
Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 4 more
Completed Phase 3 Interventional Results available

12 / 48 Week Pivotal PFT vs PBO in COPD I

NCT00782210
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI1744), placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
21
States / cities
Jasper, Alabama • Berkeley, California • Los Angeles, California + 17 more
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
79
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 61 more
Conditions
Diabetes Mellitus, Type II
Interventions
Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Concord, California • Encino, California • Escondido, California + 18 more
Completed No phase listed Observational Accepts healthy volunteers

The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat)

NCT03710278
Conditions
Meningitis, Encephalitis, Guillain-Barré, Subarachnoid Hemorrhage, Intracranial Neoplasm, Intracranial CNS Disorder
Interventions
LPat Device
Device
Lead sponsor
Spartanburg Regional Healthcare System
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Spartanburg, South Carolina
Conditions
Parkinson's Disease
Interventions
PYM50028, Placebo
Drug
Lead sponsor
Phytopharm
Industry
Eligibility
35 Years to 75 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections, Tuberculosis, Mycobacterium Infection
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Groton, Connecticut • Bethesda, Maryland
Conditions
Healthy Volunteers
Interventions
PF-04308515, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1 Interventional Accepts healthy volunteers

BK With VST for Kidney Transplant Patients

NCT05042076
Conditions
Kidney Transplant Infection, BK Virus Infection
Interventions
BK-specific T cells from Donor Lymphocytes
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Interventions
Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), Tacrolimus Capsules, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more
Conditions
Alopecia Areata
Interventions
CTP-543 matching placebo, CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Los Angeles, California + 19 more
Conditions
Stroke, Acute
Interventions
Nerinetide (NA-1), 2.6 mg/kg, Placebo
Drug
Lead sponsor
NoNO Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 17 more
Conditions
Transplant
Interventions
Health services delivery
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
2,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Conditions
Healthy Volunteers
Interventions
REGN2222
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Conditions
Orthodontic Pain
Interventions
Acetaminophen/Naproxen Sodium Fixed Combination
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years to 16 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah